Search results for "ADENOCARCINOMA"

showing 10 items of 589 documents

Salvage Therapy With Oral Metronomic Cyclophosphamide and Methotrexate for Castration refractory Metastatic Adenocarcinoma of the Prostate Resistant …

2011

Objective To investigate the activity and toxicity of metronomic chemotherapy with low-dose oral cyclophosphamide (CTX) and methotrexate (MTX) in patients with metastatic CRPC that progresses after docetaxel. Patients with castration-resistant prostate cancer (CRPC) that progresses after docetaxel may benefit from receiving further chemotherapy. Methods Patients were treated with CTX 50 mg/d p.o. plus MTX 2.4 mg p.o. twice per week without rest periods. All patients received simultaneous luteinizing hormone-releasing hormone analogue. Prostate-specific antigen (PSA) response was defined as a 50% reduction on 2 evaluations at least 4 weeks apart. Objective response was measured according to …

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentSalvage therapyPhases of clinical researchAdministration OralAntineoplastic AgentsDocetaxelAdenocarcinomaGastroenterologyCyclophosphamide docetaxel methotrexate metronomic chemotherapy prostate carcinomaSettore MED/24 - UrologiaProstate cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansTreatment FailureCyclophosphamideSalvage TherapyChemotherapyLeukopeniabusiness.industryProstatic Neoplasmsmedicine.diseaseMetronomic ChemotherapySurgeryMethotrexateDocetaxelTolerabilityAdministration MetronomicTaxoidsmedicine.symptombusinessmedicine.drug
researchProduct

Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma.

2011

OBJECTIVES To investigate cancer-related outcomes and prognostic factors of papillary renal cell carcinoma (pRCC) in a large multicentre data set. Oncological outcome and prognostic factors of pRCC have been limitedly evaluated in comparison with the most common RCC subtype, clear cell RCC. PATIENTS AND METHODS From a multicentre retrospective database, including 5463 patients who were surgically treated for RCC at 16 Italian academic centres between 1995 and 2007, 577 patients with pRCC were identified. Univariable and multivariable Cox regression models were performed to identify prognostic factors predictive of recurrence-free survival (RFS) and cancer-specific survival (CSS) after surge…

Malerenal cell carcinomaTime FactorsPapillary renal cell carcinoma; Prognostic factorsPrognosiFEATURESkidney cancer; papillaryrenal cell carcinoma; papillary adenocarcinoma; prognostic factorspapillary renal cell carcinomaNephrectomyCLASSIFICATIONFollow-Up Studiecancer-specific survivalpapillaryRisk FactorsRetrospective StudieCause of DeathPrevalenceHumansrecurrence-free survivalprognostic factorCarcinoma Renal CellTYPE-1Proportional Hazards ModelsRetrospective StudiesNeoplasm StagingAcademic Medical Centerspapillary adenocarcinomaRisk Factorkidney cancerKidney Neoplasmprognostic factorsMiddle AgedPrognosisTUMORSKidney NeoplasmsHISTOLOGIC SUBTYPESPrognostic factors in a large multi-institutional series of papillary renal cell carcinoma.Survival RateAcademic Medical CenterItalySURVIVALProportional Hazards ModelFemaleprognostic factors; papillary renal cell carcinoma; recurrence-free survival; cancer-specific survivalFollow-Up StudiesHuman
researchProduct

Electrochemical Quantification of H2O2 Released by Airway Cells Growing in Different Culture Media

2022

Quantification of oxidative stress is a challenging task that can help in monitoring chronic inflammatory respiratory airway diseases. Different studies can be found in the literature regarding the development of electrochemical sensors for H2O2 in cell culture medium to quantify oxidative stress. However, there are very limited data regarding the impact of the cell culture medium on the electrochemical quantification of H2O2. In this work, we studied the effect of different media (RPMI, MEM, DMEM, Ham’s F12 and BEGM/DMEM) on the electrochemical quantification of H2O2. The used electrode is based on reduced graphene oxide (rGO) and gold nanoparticles (AuNPs) and was obtained by co-electrode…

Mechanical EngineeringH2O2H<sub>2</sub>O<sub>2</sub>; electrochemical sensor; cell culture media; graphene oxide; gold; bronchial epithelial cell; lung adenocarcinoma cell; oxidative stress; cigarette smoke extract; resveratrolelectrochemical sensorgoldresveratrollung adenocarcinoma cellSettore ING-IND/23 - Chimica Fisica ApplicataControl and Systems Engineeringcell culture mediabronchial epithelial cellSettore ING-IND/17 - Impianti Industriali Meccanicigraphene oxideoxidative stressElectrical and Electronic Engineeringcigarette smoke extract
researchProduct

Immunocytochemical typification of mesothelial cells in effusions: in vivo and in vitro models.

1994

We have performed immunocytochemical, immunoelectron microscopy, Western blot, and culture techniques using monoclonal antibodies against cytokeratin, vimentin, and desmin on 17 benign and 20 malignant effusions of pleural and ascitic origin. Triple coexpression of these three antigens was observed in benign reactive mesothelial cells as well as in one case of mesothelioma. All metastatic adenocarcinoma cells were consistently negative to desmin and positive to cytokeratin and vimentin. Present results were helpful to distinguish reactive and malignant mesothelioma from metastatic carcinoma cells in effusions.

MesotheliomaPathologymedicine.medical_specialtyHistologyImmunoelectron microscopyBlotting WesternVimentinmacromolecular substancesBiologyAdenocarcinomaModels BiologicalEpitheliumPathology and Forensic MedicineMetastatic carcinomaDesminDiagnosis DifferentialImmunoenzyme TechniquesPleural diseaseCytokeratinmedicineAscitic FluidHumansVimentinCells CulturedGeneral Medicinemedicine.diseasePleural Effusionbiology.proteinAdenocarcinomaKeratinsDesminFemaleMesothelial CellFollow-Up StudiesDiagnostic cytopathology
researchProduct

Immunohistochemical/histochemical double staining method in the study of the columnar metaplasia of the oesophagus

2014

Intestinal metaplasia in Barrett’s oesophagus (BO) represents an important risk factor for oesophageal adenocarcinoma. Instead, few and controversial data are reported about the progression risk of columnar-lined oesophagus without intestinal metaplasia (CLO), posing an issue about its clinical management. The aim was to evaluate if some immunophenotypic changes were present in CLO independently of the presence of the goblet cells. We studied a series of oesophageal biopsies from patients with endoscopic finding of columnar metaplasia, by performing some immunohistochemical stainings (CK7, p53, AuroraA) combined with histochemistry (Alcian-blue and Alcian/PAS), with the aim of simultaneousl…

Mild Dysplasiap53MalePathologymedicine.medical_specialtyHistologyEsophageal NeoplasmsBiophysicsSettore MED/08 - Anatomia PatologicaBiologyAdenocarcinomadigestive systemBarrett EsophagusEsophagusAntigenMetaplasiamedicineHumansEsophaguslcsh:QH301-705.5Retrospective StudiesMetaplasiaStaining and LabelingBrief ReportBarrett’s oesophagusIntestinal metaplasiaCell Biologymedicine.diseaseImmunohistochemistryEpitheliumdigestive system diseasesBarrett’s oesophagus columnar-lined oesophagus p53 Aurora A kinasemedicine.anatomical_structureBarrett’s oesophagus columnar-lined oesophagus p53 Aurora A kinase.lcsh:Biology (General)columnar-lined oesophagusAdenocarcinomaImmunohistochemistryAurora A kinaseFemaleGoblet Cellsmedicine.symptomEuropean Journal of Histochemistry
researchProduct

Activation of EDTA-resistant Gelatinases in Malignant Human Tumors

2006

Abstract Among the many proteases associated with human cancer, seprase or fibroblast activation protein α, a type II transmembrane glycoprotein, has two types of EDTA-resistant protease activities: dipeptidyl peptidase and a 170-kDa gelatinase activity. To test if activation of gelatinases associated with seprase could be involved in malignant tumors, we used a mammalian expression system to generate a soluble recombinant seprase (r-seprase). In the presence of putative EDTA-sensitive activators, r-seprase was converted into 70- to 50-kDa shortened forms of seprase (s-seprase), which exhibited a 7-fold increase in gelatinase activity, whereas levels of dipeptidyl peptidase activity remaine…

Models MolecularCancer ResearchProteasesProtein ConformationDipeptidyl-peptidase activityIn situ hybridizationBiologyDipeptidyl peptidaseArticleCell LineFibroblast activation protein alphaNeoplasmsEndopeptidasesmedicineGelatinaseAnimalsHumansDipeptidyl-Peptidases and Tripeptidyl-PeptidasesEdetic AcidSerine EndopeptidasesMembrane ProteinsHaplorhinimedicine.diseaseRecombinant Proteinsseprase fibroblast activation protein alpha (FAP-α) gelatinase activation malignant tumorEnzyme ActivationOncologyBiochemistryGelatinasesCancer researchImmunohistochemistryAdenocarcinoma
researchProduct

The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Pro…

2017

Abstract Background The androgen receptor splice variant 7 (AR-V7) is associated with resistance to hormonal therapy in castration-resistant prostate cancer (CRPC). Due to limitations of the methods available for AR-V7 analysis, the identification of a reliable detection method may facilitate the use of this biomarker in clinical practice. Objective To confirm AR-V7 as a predictor of resistance to hormonal therapy and develop a new approach to assess AR-V7 by highly sensitive digital droplet polymerase chain reaction (ddPCR) in plasma-derived exosomal RNA. Design, setting, and participants Plasma samples were collected from 36 CRPC patients before they began second-line hormonal treatment. …

Oncology0301 basic medicineMaleResistanceExosomeschemistry.chemical_compoundProstate cancer0302 clinical medicineProtein IsoformsNeoplasm MetastasisReceptorAged 80 and overProstate cancerMiddle AgedProstatic Neoplasms Castration-ResistantReceptors Androgen030220 oncology & carcinogenesisBenzamidesAdenocarcinomaBiomarker (medicine)Hormonal therapyAR-V7; Digital droplet PCR; Exosomes; Hormonal therapy; Pharmacogenetics; Prostate cancer; Resistance; UrologyAndrostenesHormonal therapymedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classUrologyCastration resistantAdenocarcinomaDisease-Free Survival03 medical and health sciencesSDG 3 - Good Health and Well-beingInternal medicineNitrilesPhenylthiohydantoinmedicineEnzalutamideHumansAgedDigital droplet PCRPlasma derivedbusiness.industryRNAAndrogen Receptor Splice Variant 7medicine.diseaseAndrogenEndocrinology030104 developmental biologychemistryPharmacogeneticsDrug Resistance NeoplasmCancer cellCancer researchRNAAR-V7businessPharmacogenetics
researchProduct

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer p…

2011

Bevacizumab, is a humanized monoclonal antibody to vasculo-endothelial- growth-factor, with anticancer activity in non-small-cell-lung cancer (NSCLC) patients. Our previous results from a dose/finding phase I trial in NSCLC patients, demonstrated the anti-angiogenic effects and toxicity of a newest bevacizumab-based combination with fractioned cisplatin and daily oral etoposide. We designed a phase II trial to evaluate in advanced NSCLC patients the antitumor activity and the safety of this novel regimen. In particular, 45 patients (36 males and 9 females), with a mean age of 54 years, an ECOG ≤2, stage III B/IV and NSCLC (28 adenocarcinomas, 11 squamous-cell carcinomas, 2 large-cell carcin…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsBevacizumabDose-dense chemotherapyAdenocarcinomaNSCLCAntibodies Monoclonal HumanizedDrug Administration ScheduleInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsDose/dense-metronomic-chemotherapymedicineHumansLung cancerAgedEtoposideNeoplasm StagingPharmacologyCisplatinbusiness.industryCancerAntibodies MonoclonalmPEBev regimenMiddle Agedmedicine.diseaseVEGFBevacizumabRegimenOncologyToxicityCarcinoma Squamous CellMolecular MedicineEvery Three WeeksCarcinoma Large CellFemaleCisplatinbusinessmedicine.drugCancer biologytherapy
researchProduct

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy

2010

Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients eligible for second-line treatment is scarce. The aim of this study was to assess the prognostic role of a number of routinely collected clinical variables and to provide a summary index to discriminate patients according to probability of survival.Methods: individual data from nine randomised trials of second-line treatment in advanced NSCLC were analysed. Primary end-point was overall survival (OS). Cox model, stratified by trial, was used for multivariate analyses, and a prognostic index was provided and validated according to an internal/external procedure.Results: Out of 1239 patients, 119…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyMultivariate analysisLung NeoplasmsWEEKLY DOCETAXELIRINOTECANCOMBINATION CHEMOTHERAPYAntineoplastic AgentsERLOTINIBPrognostic factorsNSCLCTHERAPYPooled analysisPLUS GEMCITABINEInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansStage (cooking)Lung cancerEVERY 3 WEEKSAgedNeoplasm StagingRandomized Controlled Trials as TopicAged 80 and overPerformance statusProportional hazards modelbusiness.industryAge FactorsCombination chemotherapyPHASE-III TRIALMiddle Agedmedicine.diseasePrognosisTreatment OutcomeOncologyMeta-analysisPrognostic scoreCOMPARING DOCETAXELSecond-line treatmentAdenocarcinomaFemalebusinessEpidemiologic MethodsNon-small-cell lung cancerEuropean Journal of Cancer
researchProduct

Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer

2020

Abstract Background Immune response against cancer has prognostic impact but its role in gastric cancer is poorly known. The aim of the study was to assess the prognostic significance of immune cell score (CD3+, CD8+), tumour immune escape (PD-L1, PD-1) and immune tolerance (Clever-1). Methods After exclusion of Epstein-Barr virus positive (n = 4) and microsatellite instable (n = 6) tumours, the study included 122 patients with GC undergoing D2 gastrectomy. CD3+ and CD8+ based ICS, PD-L1, PD-1 and Clever-1 expressions were evaluated. Differences in survival were examined using Cox regression adjusted for confounders. The primary outcome was 5-year survival. Results The 5-year overall surviv…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyProgrammed Cell Death 1 ReceptorAdenocarcinomaArticleB7-H1 AntigenImmune toleranceImmunophenotyping03 medical and health sciences0302 clinical medicineImmunophenotypingImmune systemStomach NeoplasmsInternal medicinePD-L1medicineImmune ToleranceHumansAgedbiologyMolecular medicinebusiness.industryProportional hazards modelMacrophagesConfoundingImmunosurveillancemahasyöpäCancerennusteetMiddle Agedmedicine.diseaseOncologyimmuunivaste030220 oncology & carcinogenesisbiology.proteinsyöpätauditfenotyyppiFemaleTumor EscapebusinessCD8Signal TransductionBritish Journal of Cancer
researchProduct